Here are three highlights:
1. The patent is for chondrocyte or like cell production to leverage “fibroblasts in vivo with mechanical stress and low oxygen tension.”
2. SpinalCyte is a tissue engineering technology company developing products to re-grow the spinal disc nucleus with human dermal fibroblasts.
3. The company now has 24 U.S. and foreign patents, with 45 pending patents.
More articles on devices:
Relievant Medsystems appoints Kevin Hykes CEO: 4 takeaways
Medovex launches facet joint syndrome relief device in Spain: 5 insights
Implanet reports 19% increase in spine revenue for 1st half of 2017: 7 key points
